Inventiva's Stock Jumps 5.19% at Opening, Boosted by Record Fundraising

Record Fundraising Finalized in November

The biopharmaceutical company finalized a fundraising in November exceeding 139 million euros, allowing it to finance its operations until the first quarter of 2027. Over the week, Inventiva has gained 14.66%, while since the beginning of the year, the stock has shown a performance of 62.22%, significantly outperforming the CAC 40 at 10.88%. The current volume remains moderate with only 0.06% of the capital traded this morning, contrasting with the liveliness observed in recent days. The last three months marked a slight decline of 1.99%, a correction that today's session seems to surpass.

Technical Position Strengthened Above Moving Averages

Technically, Inventiva consolidates its position above its 50-day moving average established at 3.93 euros, where the stock is trading at 3.95 euros this morning, confirming a trend reversal. The 200-day moving average remains well established at 3.29 euros, consolidating the bullish framework over the past year. The Relative Strength Index (RSI), at 55, remains in the neutral zone and leaves room for the movement to continue. This median position reflects an absence of overbought or oversold conditions, favoring the continuation of the positive momentum.

Market Flows Indicate Buyer Dominance

In terms of market flows, the Chaikin Money Flow shows a positive value at 0.12, confirming that buyers outweigh sellers, while the MACD histogram shifts into positive territory (0.05), signaling a possible reversal of dynamics after a neutral period. The volatility of the stock reaches 23.21% over a month, a characteristic typical of biotechnological values in clinical development, while the beta of -0.49 indicates a significant decorrelation with the CAC 40, which gains 0.26% this morning. This independence confirms that the movement responds to elements specific to Inventiva rather than a general trend of the Parisian market.